Bioavailability and Bioequivalence

Bioavailability involves the degree and velocity at which a drug is absorbed into the bloodstream, rendering it accessible to its designated tissue or organ. A drug's total bioavailability is less than one when administered through an extravascular route. Various physiological factors can limit the availability of medications before they reach the bloodstream. Absorption is influenced by food intake, and concurrent medications can alter absorption and first-pass metabolism. The drug termination can be influenced by intestinal motility, and the chemical breakdown of compounds may be impacted by the presence of intestinal micro flora.

Bioequivalence compares the bioavailability of distinct formulations of a given drug. When two formulations demonstrate bioequivalence, it is anticipated that they will generate comparable therapeutic effects. This is particularly important in generic drug development, where ensuring bioequivalence to the original branded product is essential for regulatory approval. Numerous factors, such as drug formulation, route of administration, and patient-specific characteristics, can exert an influence on both bioavailability and bioequivalence.